Literature DB >> 10389348

Should ablation of atrial flutter be discouraged in patients with documented atrial fibrillation?

P Della Bella1, S Riva, P Galimberti.   

Abstract

Atrial fibrillation and atrial flutter often coexist in the same patient. The purpose of this article is to provide an analysis of the mechanisms underlying the transformation from atrial fibrillation into atrial flutter and to investigate the long-term clinical benefits following ablation of atrial flutter in relation to recurrences of atrial fibrillation. Experimental studies in the human atrium demonstrated that in most instances atrial fibrillation is a triggering rhythm for atrial flutter. However, a review of the most recent studies shows a low percentage of recurrence of atrial fibrillation after successful catheter ablation for atrial flutter. The risk factors for this recurrence are the presence of structural heart disease, increased left atrial dimension and volume, a previous history of atrial fibrillation, and the failure of multiple antiarrhythmic drugs, inducibility of atrial fibrillation by a standard programmed electrical stimulation protocol after catheter ablation. These data, together with the high success rate of catheter ablation for atrial flutter, suggest to perform radiofrequency catheter ablation for atrial flutter in patients with documented atrial fibrillation.

Entities:  

Mesh:

Year:  1999        PMID: 10389348

Source DB:  PubMed          Journal:  Cardiologia        ISSN: 0393-1978


  2 in total

1.  Frequency of atrial arrhythmias after atrial flutter ablation and the effect of presenting rhythm on the day of ablation.

Authors:  Anupama Vasudevan; Aneley Hundae; Darara Borodge; Peter A McCullough; Peter J Wells
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-14

2.  Risk and outcome after ablation of isthmus-dependent atrial flutter in elderly patients.

Authors:  Béatrice Brembilla-Perrot; Jean Marc Sellal; Arnaud Olivier; Vladimir Manenti; Thibault Villemin; Daniel Beurrier; Christian De Chillou; Zohra Lamiral; Nicolas Girerd
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.